TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07845500: A PHASE 3 STUDY TO EVALUATE THE SWITCH TO MONTHLY BEROBENATIDE FOR MAINTAINING WEIGHT IN ADULTS WHO ARE ON WEEKLY SEMAGLUTIDE OR TIRZEPATIDE (VESPER-SWITCH)

Sponsor: Pfizer · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 660 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$11,220,272

Rescue Site Savings

+$7,401,608

Unlock Full NCT07845500 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07845500 Rescue Dossier →